Clincosm LogoSign in Get a demo

carcinoma, bronchogenic

Showing 1 - 16 of 16
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +14 more
  • Glendale, California
  • +12 more
Feb 2, 2023

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

Recruiting
  • Non-Small Cell Lung Cancer
  • +13 more
  • furmonertinib 240 mg
  • +2 more
  • Yuma, Arizona
  • +37 more
Dec 14, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

Tumors, Colorectal Tumors, Melanoma Trial in United States (Alectinib)

Terminated
  • Neoplasms
  • +27 more
  • Culver City, California
  • +28 more
Jul 25, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Pralsetinib to Best Available Therapy in RET-Fusion Positive

Enrolling by invitation
  • RET-fusion Non Small Cell Lung Cancer
  • +16 more
    • New York, New York
    • +2 more
    Aug 9, 2021

    Stage IV, NSCLC, Lung Tumors, Bronchial Tumors Trial in Italy (Carboplatin, Gemcitabine, Pemetrexed)

    Recruiting
    • Stage IV, NSCLC
    • +8 more
    • Meldola, Forlì, Italy
    • +27 more
    Nov 3, 2020

    Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Shanghai (SHR-1210, Carboplatin, Pemetrexed)

    Completed
    • Lung Neoplasms
    • +8 more
    • SHR-1210
    • +2 more
    • Shanghai, Shanghai, China
      Tongji University, Shanghai Pulmonary Hospital
    Jun 7, 2020

    Lung Tumors, Thoracic Surgery, NSCLC Trial in Shanghai (Subxiphoid uniportal VATS, Intercostal uniportal VATS)

    Completed
    • Lung Neoplasms
    • +5 more
    • Subxiphoid uniportal VATS
    • Intercostal uniportal VATS
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Feb 28, 2020

    Lung Tumors, NSCLC, Respiratory Tract Tumors Nec Trial in Guangzhou (SHR-1210)

    Unknown status
    • Lung Neoplasms
    • +6 more
    • SHR-1210
    • Guangzhou, Guangdong, China
      Guangdong Lung Cancer Institute (GLCI),Guangdong General Hospita
    Sep 7, 2018

    Tumors, Carcinoma, Bronchogenic, Breast Carcinoma Trial in Wuxi (18F-Al-NOTA-PRGD2 PET/CT)

    Unknown status
    • Tumors
    • +5 more
    • 18F-Al-NOTA-PRGD2 PET/CT
    • Wuxi, Jiangsu, China
      Wuxi No. 4 People's Hospital
    Mar 9, 2017

    Circulating Tumor DNA in Late Stage NSCLC Patients

    Unknown status
    • Carcinoma, Non-Small-Cell Lung
    • +4 more
      • Wenzhou, Zhejiang, China
        Wenzhou Medical University
      Oct 31, 2016

      Lung Tumor, Carcinoma, Bronchogenic Trial in Newport Beach, Metairie, Dallas (Lucanix)

      Completed
      • Lung Neoplasm
      • Carcinoma, Bronchogenic
      • Lucanix
      • Newport Beach, California
      • +2 more
      Jul 28, 2010

      Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic Trial in Houston (Motexafin Gadolinium Injection)

      Completed
      • Non-Small-Cell Lung Carcinoma
      • Carcinoma, Bronchogenic
      • Motexafin Gadolinium Injection
      • Houston, Texas
        The University of Texas MD Anderson Cancer Center
      Apr 2, 2009